Last reviewed · How we verify
beta-cell autoantibody dosage — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
beta-cell autoantibody dosage (beta-cell autoantibody dosage) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| beta-cell autoantibody dosage TARGET | beta-cell autoantibody dosage | Assistance Publique - Hôpitaux de Paris | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- beta-cell autoantibody dosage CI watch — RSS
- beta-cell autoantibody dosage CI watch — Atom
- beta-cell autoantibody dosage CI watch — JSON
- beta-cell autoantibody dosage alone — RSS
Cite this brief
Drug Landscape (2026). beta-cell autoantibody dosage — Competitive Intelligence Brief. https://druglandscape.com/ci/beta-cell-autoantibody-dosage. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab